Therefore, FGF21 shows therapeutic potential to treat obesity-related metabolic complications, including hyperglycemia, insulin resistance, and non-alcoholic fatty liver disease (NAFLD)24–27. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.